Stayble Therapeutics clinical phase IIb study with STA363 takes no break in the summer heat. Approximately 90% of the patients have now completed their 12-month follow-up, which shows that the company has good opportunities to present top-line data during the fourth quarter of this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2585 SEK | +2.17% | -0.96% | -14.69% |
1st Jan change | Capi. | |
---|---|---|
-14.69% | 774K | |
+8.92% | 114B | |
+10.48% | 105B | |
-1.83% | 21.73B | |
-6.45% | 23.83B | |
-10.39% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Therapeutics Phase IIb Study Nears the Final Line